Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/1695
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorBARBOSA, Joao Arthur B. A.-
dc.contributor.authorMURACCA, Eduardo-
dc.contributor.authorNAKANO, Elcio-
dc.contributor.authorPARANHOS, Mario-
dc.contributor.authorNATALINO, Renato-
dc.contributor.authorCORDEIRO, Paulo-
dc.contributor.authorSROUGI, Miguel-
dc.contributor.authorANTUNES, Alberto Azoubel-
dc.date.accessioned2013-09-23T16:30:06Z-
dc.date.available2013-09-23T16:30:06Z-
dc.date.issued2013-
dc.identifier.citationUROLOGY, v.82, n.1, p.182-188, 2013-
dc.identifier.issn0090-4295-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/1695-
dc.description.abstractOBJECTIVE To evaluate the association of male lower urinary tract symptoms (LUTS) with metabolic syndrome (MetS) and androgenetic alopecia in a Latin American population. METHODS We enrolled 907 patients for prospective evaluation at a single institution. LUTS were evaluated with the International Prostate Symptom Score (IPSS). Subjects were evaluated with respect to hypertension, diabetes, dyslipidemia, previous cardiovascular events, body mass index (BMI), waist and hip circumference, and a laboratorial investigation including prostate-specific antigen (PSA), C-reactive protein (CRP), and gonadal steroids. Alopecia was classified according to the Norwood-Hamilton scale. RESULTS Mean patient age was 61.0 years; 57.5% of subjects had moderate/severe LUTS; MetS was present in 17.2% of subjects and 53.9% were classified as bald. Age, hypertension, diabetes, dyslipidemia, alopecia, previous cardiovascular event, and elevated waist-to-hip ratio (WHR) were associated with moderate/severe LUTS and with storage symptoms (P < .05). On multivariable analysis, age (odds ratio [OR] 2.30, 95% confidence interval [CI] 1.63-3.25), cardiovascular events (OR 1.73, 95% CI 1.07-2.78), and WHR (OR 1.65, 95% CI 1.13-2.40) were independent predictors for LUTS. For storage symptoms, age (OR 1.80, 95% CI 1.28-2.54), cardiovascular event (OR 2.07, 95% CI 1.27-3.39), WHR (OR 1.54, 95% CI 1.06-2.25), and MetS (OR 1.70, 95% CI 1.01-2.86) were independent risk factors. Age and cardiovascular event were the only independent predictors for voiding symptoms. CONCLUSION Components of the MetS were strongly associated with moderate and severe LUTS. WHR and cardiovascular events were independent predictors of voiding and storage symptoms, and MetS was an independent predictor of storage symptoms. Alopecia was not an independent predictor of LUTS. UROLOGY 82: 182-188, 2013. (C) 2013 Elsevier Inc.-
dc.language.isoeng-
dc.publisherELSEVIER SCIENCE INC-
dc.relation.ispartofUrology-
dc.rightsrestrictedAccess-
dc.subject.otherbenign prostatic hyperplasia-
dc.subject.othermale pattern baldness-
dc.subject.othersteroid-hormones-
dc.subject.othermen-
dc.subject.otherassociation-
dc.subject.otherhealth-
dc.subject.otherneurodegeneration-
dc.subject.otherdutasteride-
dc.subject.otherfinasteride-
dc.subject.otherprevalence-
dc.titleRisk Factors for Male Lower Urinary Tract Symptoms: The Role of Metabolic Syndrome and Androgenetic Alopecia in a Latin American Population-
dc.typearticle-
dc.rights.holderCopyright ELSEVIER SCIENCE INC-
dc.identifier.doi10.1016/j.urology.2013.03.001-
dc.identifier.pmid23642850-
dc.subject.wosUrology & Nephrology-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.description.beginpage182-
hcfmusp.description.endpage188-
hcfmusp.description.issue1-
hcfmusp.description.volume82-
hcfmusp.origemWOS-
hcfmusp.origem.id2-s2.0-84879553884-
hcfmusp.origem.idWOS:000321036200049-
hcfmusp.publisher.cityNEW YORK-
hcfmusp.publisher.countryUSA-
hcfmusp.relation.referenceAlberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644-
hcfmusp.relation.referenceArias-Santiago S, 2012, J AM ACAD DERMATOL, V66, P401, DOI 10.1016/j.jaad.2010.12.023-
hcfmusp.relation.referenceArias-Santiago S, 2010, J AM ACAD DERMATOL, V63, P420, DOI 10.1016/j.jaad.2009.10.018-
hcfmusp.relation.referenceAzadzoi KM, 2007, J UROLOGY, V178, P710, DOI 10.1016/j.juro.2007.03.096-
hcfmusp.relation.referenceCellek S, 1999, BRIT J PHARMACOL, V128, P1804, DOI 10.1038/sj.bjp.0702981-
hcfmusp.relation.referenceChen WC, 2004, ARCH DERMATOL RES, V296, P245, DOI 10.1007/s00403-004-0514-z-
hcfmusp.relation.referenceGao Y, 2012, UROLOGY, V79, P194, DOI 10.1016/j.urology.2011.07.1399-
hcfmusp.relation.referenceGuarrera M, 2009, Int J Trichology, V1, P120, DOI 10.4103/0974-7753.58554-
hcfmusp.relation.referenceGupta A, 2006, UROLOGY, V68, P1198, DOI 10.1016/j.urology.2006.09.034-
hcfmusp.relation.referenceHammarsten J, 2001, EUR UROL, V39, P151, DOI 10.1159/000052430-
hcfmusp.relation.referenceJin B, 1999, J CLIN ENDOCR METAB, V84, P3613, DOI 10.1210/jc.84.10.3613-
hcfmusp.relation.referenceKupelian V, 2013, J UROLOGY, V189, pS107, DOI 10.1016/j.juro.2012.11.026-
hcfmusp.relation.referenceLee RK, 2012, BJU INT, V110, P540, DOI 10.1111/j.1464-410X.2011.10819.x-
hcfmusp.relation.referenceMontorsi F, 2011, BJU INT, V107, P1426, DOI 10.1111/j.1464-410X.2011.10129.x-
hcfmusp.relation.referenceNeuhouser ML, 2004, UROLOGY, V64, P201, DOI 10.1016/j.urology.2004.04.025-
hcfmusp.relation.referenceNickel JC, 2011, BJU INT, V108, P388, DOI 10.1111/j.1464-410X.2011.10195.x-
hcfmusp.relation.referenceNORWOOD OT, 1975, SOUTHERN MED J, V68, P1359-
hcfmusp.relation.referenceOh BR, 1998, UROLOGY, V51, P744, DOI 10.1016/S0090-4295(98)00108-3-
hcfmusp.relation.referenceOhgaki K, 2011, UROLOGY, V77, P1432, DOI 10.1016/j.urology.2010.12.024-
hcfmusp.relation.referenceRohrmann S, 2005, INT J OBESITY, V29, P310, DOI 10.1038/sj.ijo.0802881-
hcfmusp.relation.referenceRossi A, 2011, DERMATOL THER, V24, P455, DOI 10.1111/j.1529-8019.2011.01441.x-
hcfmusp.relation.referenceSeveri G, 2003, BRIT J DERMATOL, V149, P1207, DOI 10.1111/j.1365-2133.2003.05565.x-
hcfmusp.relation.referenceShenfeld OZ, 2005, UROLOGY, V65, P181, DOI 10.1016/j.urology.2004.08.055-
hcfmusp.relation.referenceSu LH, 2010, BRIT J DERMATOL, V163, P371, DOI 10.1111/j.1365-2133.2010.09816.x-
hcfmusp.relation.referenceTemml C, 2009, UROLOGY, V73, P544, DOI 10.1016/j.urology.2008.10.027-
hcfmusp.relation.referenceVignozzi L, 2012, J ENDOCRINOL, V212, P71, DOI 10.1530/JOE-11-0289-
hcfmusp.relation.referenceYang TK, 2012, UROLOGY, V80, P1093, DOI 10.1016/j.urology.2012.08.002-
hcfmusp.relation.referenceYip L, 2011, AUSTRALAS J DERMATOL, V52, P81, DOI 10.1111/j.1440-0960.2011.00745.x-
hcfmusp.relation.referenceZhu YS, 2009, ANN NY ACAD SCI, V1155, P43, DOI 10.1111/j.1749-6632.2009.04115.x-
dc.description.indexMEDLINE-
hcfmusp.citation.scopus13-
hcfmusp.scopus.lastupdate2022-05-06-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCG
Departamento de Cirurgia - FM/MCG

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/55
LIM/55 - Laboratório de Urologia

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
File Description SizeFormat 
art_BARBOSA_Risk_Factors_for_Male_Lower_Urinary_Tract_Symptoms_2013.PDF
  Restricted Access
publishedVersion (English)414.77 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.